MedTrace Logo

A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD)

NCT01085162 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2013-04-04

No results posted yet for this study

Summary

This long-term study will follow patients with known or suspected of having coronary artery disease (CAD) and have participated in present and future BMS747158 clinical studies. The purpose of this study is to evaluate the long-term predictive value associated with BMS747158 Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI).

Conditions

  • Coronary Artery Disease (CAD)

Interventions

DRUG

BMS747158

BMS747158 is a novel PET MPI agent labeled with Fluorine-18.

Sponsors & Collaborators

  • Lantheus Medical Imaging

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01085162 on ClinicalTrials.gov